CYPH Overview

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Wall Street analysts forecast CYPH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cypherpunk Technologies Inc revenue for the last quarter amounts to 0.00 USD, decreased

Cypherpunk Technologies Inc. EPS for the last quarter amounts to -0.08 USD, decreased -81.82

Cypherpunk Technologies Inc (CYPH) has 52 emplpoyees as of March 05 2026.

Today CYPH has the market capitalization of 40.56M USD.